secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2025-06-16T23:59:59+00:00
Accession:  0001193125-25-141085
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics prices $200M public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Offering of 8.39M shares at $19.66/share and 1.78M pre-funded warrants at $19.659/warrant; gross proceeds ~$200M.
- Underwriters granted 30-day option to purchase additional 1.53M shares; expected close June 16, 2025.
- Net proceeds including option exercise expected ~$216.1M, for working capital and general corporate purposes.
- Joint book-runners: Jefferies, Goldman Sachs, TD Cowen, Mizuho; LifeSci Capital as lead manager.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312525141085/0001193125-25-141085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312525141085/d150245d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-141085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer